Stewart Parker Buys Shares of CDXS $CDXS
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Stewart Parker, insider at Codexis, Inc. ($CDXS), bought 66,350 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Codexis, Inc. Stock Up 56.0%
Shares of Codexis, Inc. ($CDXS) traded around $2.48 on Thursday, up 56.0% for the day.
Codexis, Inc. Earnings
Analysts Set New Price Targets
About Codexis, Inc.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Get Codexis, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CDXS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.